-
Mashup Score: 3
Monika Joshi, MD, MRCP, of Penn State Cancer Institute, contextualizes the results of the THOR study within the treatment landscape for FGFR2/3-altered advan…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2New Noninvasive Urine Test Can Reduce Unnecessary Biopsies in Advanced Prostate Cancer | GU Oncology Now - 2 day(s) ago
A new 18-gene urine test developed by Dr. Jeffrey Tosoian and colleagues can improve PSA screening outcomes relative to existing biomarker tests in patients with high-grade PCa.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9The Uromigos Episode 310: Dosing and Duration of Drugs From a Cost Perspective | GU Oncology Now - 3 day(s) ago
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune checkpoint inhibitors.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Daniel Spratt, MD β Offering Mentorship, Purpose for Aspiring Radiation Oncologists | GU Oncology Now - 4 day(s) ago
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5Evaluating Gemcitabine, Docetaxel Versus Bacillus Calmette-GuΓ©rin in Patients With UTUC | GU Oncology Now - 5 day(s) ago
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-GuΓ©rin.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9The Uromigos Episode 310: Dosing and Duration of Drugs From a Cost Perspective | GU Oncology Now - 6 day(s) ago
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune checkpoint inhibitors.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
π Don't miss our latest video where @MonikaJoshimd contextualizes the results of the #THOR study within the treatment landscape for FGFR2/3-altered advanced #UC. π₯ Watch Here: https://t.co/gM1PUPxXYr